Systemic antifungal therapy in critically ill patients without invasive fungal infection*.
about
Point of Care Testing for the Diagnosis of Fungal Infections: Are We There Yet?Candida colonization index and subsequent infection in critically ill surgical patients: 20 years laterT2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasisIntensive care medicine research agenda on invasive fungal infection in critically ill patients.Invasive candidiasis: from mycobiome to infection, therapy, and prevention.Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis.Epidemiology and antifungal susceptibility of Candida species in a tertiary care hospital, Kolkata, IndiaEMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trialEmpirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICUManagement of invasive candidiasis in nonneutropenic ICU patients.How much European prescribing physicians know about invasive fungal infections management?Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patientsAntifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study.Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study.Characteristics and outcomes of anti-infective de-escalation during health care-associated intra-abdominal infectionsContribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditionsAppropriate Treatment of Invasive Candidiasis in ICU: Timing, Colonization Index, Candida Score & Biomarkers, Towards de-Escalation?Factors predicting prolonged empirical antifungal treatment in critically ill patients.Immunodetection of fungal and oomycete pathogens: established and emerging threats to human health, animal welfare and global food security.What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients.Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis.The current treatment landscape: candidiasis.Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases.Serum 1,3-beta-d-glucan for antifungal treatment stratification at the intensive care unit and the influence of surgery.(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.Candida albicans Germ-Tube Antibody: Evaluation of a New Automatic Assay for Diagnosing Invasive Candidiasis in ICU Patients.Dying with or Because of Invasive Fungal Infection? The Role of Immunity Exhaustion on Patient Outcome.Should we Administer Antifungal Drugs Before the Diagnosis of Invasive Fungal Infection in Non-Neutropenic Critically Ill Patients?Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain.Impact of systemic antifungal therapy on the detection of Candida species in blood cultures in clinical cases of candidemia.Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization.Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients.Antifungal use in intensive care units: another uncertainty that highlights the need for precision medicine.What is the role of empirical treatment for suspected invasive candidiasis in non-neutropenic non transplanted patients in the intensive care unit?-Empiricus strikes back!Candidemia and non-candidemia related septic shock: are there differences between them?Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial.What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety.
P2860
Q26746020-8D0CA39B-8AC4-459D-BA98-A9513898C368Q27012454-46E91D3E-1D37-49D5-86CE-EDBABCAC3893Q28084998-12191FBF-A589-4466-83BA-8271362F06F0Q30235457-ED89DCD6-7C8C-4DB9-A78A-969631B4B684Q30251428-94CF8FF9-9669-47EC-89C8-9B873AC88DE2Q33703531-6CD60402-AABD-4708-87A5-363016232F05Q33851338-2FB83973-BACA-4A83-A595-4C42085989A7Q34465297-EE28BA07-F209-42A3-BE73-40D8EE4DCECAQ34487220-18AEF469-6725-4480-951C-6F5DFC849D8DQ35122093-34A4F7F0-33F9-4DBD-9905-3538C3311AC4Q35131938-9449C980-A831-445C-94EA-D38BD1806242Q35575320-C30A3107-E428-4455-9911-EDE413A7D5ECQ35775400-4206096F-2C7F-4628-83A2-702043F6F09BQ36257873-D6CFD2B0-5183-4B45-BDF2-9D348816D33EQ36441468-EA4ED180-E409-4358-AAB7-32D44F59F9A8Q36774787-D70C3804-AFE7-4471-86C8-D77770BBAC25Q36902916-E20597E0-EF86-41EA-A781-09C030844AB1Q37551817-5E3B6AB1-3F8A-40F8-8B43-CAB85F96E583Q37699716-3851CA6A-43F0-4F0A-A2F0-8B8B3FF2B374Q38111802-F0927989-F53C-44F4-9C2B-9361FF00C778Q38203447-7BAC75C1-4338-4019-9F73-0C3B5B51998CQ38589279-BF6BA4E7-9EC7-4ADA-8EF4-B24E6D649075Q39018200-AFE61CAA-52CB-47D1-ADD8-D5FA1745F631Q39367515-DFEC8657-F07B-4DFD-865E-06F01E5E99A8Q39367519-8AD743C0-A5C6-446A-81CD-0D1D406EBD19Q39812922-6753F596-9CEE-4AAD-90D3-38448DFB3958Q40264319-19ABD2E1-FEDB-40CD-B072-0BFC36B2F2C6Q40383367-B043B870-9CA7-4019-BB27-0D01BA5BA5DFQ40383385-8369A527-7954-4DC5-9F41-C3FBC20F29E6Q40533714-4E0D2F27-A399-4406-98D4-AF0253046C31Q40730760-5D09793B-C063-4FDD-BD59-9359E2624445Q41031258-DF2E0CFA-8022-4AED-B7AE-2BABDDE67FCFQ41038889-B18527DD-9E5B-4A7B-83E0-5AC179406036Q41204913-839CC972-794E-4983-8680-9A5C135183CDQ42331417-49E1D0B2-9EA4-4ADD-BBB2-E21F0908BC65Q42331462-6FA8E30B-FD74-4778-ACD9-77E75F4E2480Q45197381-06EA79DA-6163-44DF-9AD0-8F698B37973CQ47678193-E57DAB03-E464-431E-B46B-7A26603EAECAQ47749829-1B467D31-B8B9-442E-AE3A-C0541FA10387Q52575674-9429DF45-1CC5-42D5-A3B6-B87F247AFF78
P2860
Systemic antifungal therapy in critically ill patients without invasive fungal infection*.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Systemic antifungal therapy in ...... ut invasive fungal infection*.
@en
Systemic antifungal therapy in ...... ut invasive fungal infection*.
@nl
type
label
Systemic antifungal therapy in ...... ut invasive fungal infection*.
@en
Systemic antifungal therapy in ...... ut invasive fungal infection*.
@nl
prefLabel
Systemic antifungal therapy in ...... ut invasive fungal infection*.
@en
Systemic antifungal therapy in ...... ut invasive fungal infection*.
@nl
P2093
P1476
Systemic antifungal therapy in ...... ut invasive fungal infection*.
@en
P2093
Adrien Francais
Bertand Guidet
Claude Martin
Elie Azoulay
Hervé Dupont
Jean-François Timsit
Jean-Paul Stahl
P304
P356
10.1097/CCM.0B013E318236F297
P407
P577
2012-03-01T00:00:00Z